{"filings":[{"id":95853,"accession_number":"0001823239-26-000022","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai LifeSciences Q1 revenue up 41% to $65.8M; raises full-year guidance","event_type":"earnings","confidence":"high","bullets":["Q1 2026 revenue $65.8M, up 40.5% YoY; net loss improved to $(6.4)M from $(52.9)M.","Adjusted EBITDA of $20.3M vs $(10.5)M prior year; generated $4.2M free cash flow.","TriLink revenue up 65.1% to $47.5M, driven by $14.3M COVID CleanCap orders; base TriLink up 15.4%.","Cygnus revenue $18.4M, up 1.4% due to strong North America/EMEA, offset by China timing.","Full-year 2026 revenue and Adjusted EBITDA guidance raised reflecting Q1 strength and improved visibility."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":65837000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109203,"accession_number":"0001823239-26-000005","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai Q4 revenue $49.9M, net loss $63M; guides 2026 revenue $200-210M","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $49.9M, net loss $(63.0)M, positive Adj EBITDA $0.5M (non-GAAP).","Full year 2025 revenue $185.7M, net loss $(230.8)M, Adj EBITDA $(31.2)M.","Introduces 2026 revenue guidance $200M-$210M and Adj EBITDA guidance $18M-$20M.","CEO cites strong execution, exceeding revenue expectations, returning to positive Adj EBITDA.","Organizational restructuring and operating cost reduction ahead of plan."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":185743000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125698,"accession_number":"0001823239-25-000117","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai Q3 revenue $41.6M, net loss $45.1M, Adj EBITDA -$10.8M","event_type":"earnings","confidence":"high","bullets":["Revenue of $41.6 million, net loss of $45.1 million, and Adjusted EBITDA loss of $10.8 million for Q3 2025.","Full-year 2025 revenue guidance of approximately $185 million, excluding potential high-volume CleanCap orders.","CEO expects double-digit sequential revenue growth in Q4 2025, citing strong funnel and order velocity at TriLink.","Organizational restructuring and operating cost reduction initiatives remain on track."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":135877000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125697,"accession_number":"0001823239-25-000113","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Maravai LifeSciences reduces board from 11 to 8; three directors resign","event_type":"leadership","confidence":"high","bullets":["Benjamin Daverman, Jessica Hopfield, and Murali Prahalad resigned from the Board effective Oct 21, 2025.","Board size reduced from 11 to 8 directors effective Oct 27, 2025; resignations were not due to any disagreement.","R. Andrew Eckert named chair of Nominating, Governance and Risk Committee and member of Audit Committee.","Gregory T. Lucier appointed to Nominating, Governance and Risk Committee; unvested RSUs for departing directors accelerated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142427,"accession_number":"0001823239-25-000105","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","2.05","5.02","9.01"],"status":"ready","headline":"Maravai Q2 revenue down 32% to $47.4M; net loss $69.8M; restructuring cuts 25% of workforce","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $47.4M (-32% YoY); net loss $69.8M (incl. $30.4M goodwill impairment); adjusted EBITDA -$10.4M vs +$13.0M.","Announced restructuring targeting >$50M annualized savings; workforce reduction of ~25% with $8-9M severance costs.","Withdrew 2025 revenue guidance pending new leadership's business review.","CEO Bernd Brust recently appointed; EVP CCO Rebecca Buzzeo and EVP CAO Pete Leddy departing.","Base business revenue (ex high-volume CleanCap) grew 5% YoY; positive free cash flow expected by H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":94247000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142426,"accession_number":"0001823239-25-000099","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Maravai LifeSciences dismisses EY, appoints Deloitte; material weakness disclosed","event_type":"other_material","confidence":"high","bullets":["EY dismissed as auditor; Deloitte appointed effective July 16, 2025 for FY 2025.","EY's audit reports on financial statements for 2023 and 2024 were unqualified.","EY's internal control report for 2024 contained an adverse opinion citing material weaknesses in revenue/AR and goodwill impairment.","No disagreements on accounting principles or reportable events other than the internal control weakness.","Company did not consult Deloitte before the appointment; EY letter filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160466,"accession_number":"0001193125-25-146905","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Maravai LifeSciences appoints Rajesh Asarpota as CFO effective June 30, 2025, succeeding Kevin Herde","event_type":"leadership","confidence":"high","bullets":["Rajesh Asarpota appointed EVP and CFO effective June 30, 2025; Kevin Herde transitions to advisory role through Jan 31, 2026.","Asarpota receives $550k base salary, 70% target bonus, $200k cash sign-on bonus, and equity awards (333,333 options, 500k RSUs, 750k PSUs).","Previous CFO Kevin Herde entitled to severance payments per May 2023 employment agreement upon signing separation agreement.","Company not reaffirming or withdrawing FY2025 guidance; will review during Q2 2025 earnings call in August."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160465,"accession_number":"0001193125-25-137478","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Maravai LifeSciences appoints Bernd Brust as CEO, succeeding William Martin","event_type":"leadership","confidence":"high","bullets":["Bernd Brust named CEO and board member effective June 8, 2025; William Martin resigned as CEO and from board.","Brust's base salary is $750,000 with a target annual cash bonus of 100% of base salary.","Equity awards: 1M stock options, 2M RSUs, 2.25M PSUs; options and RSUs vest over three years.","Martin's departure not due to any disagreement; he is eligible for severance per existing agreement.","Company will revisit FY2025 guidance in August Q2 earnings call after Brust's assessment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160464,"accession_number":"0001823239-25-000065","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Maravai shareholders elect 4 directors, ratify EY, approve say-on-pay at 2025 meeting","event_type":"other_material","confidence":"high","bullets":["Elected Sean Cunningham, John DeFord, Jessica Hopfield, Murali Prahalad as directors for three-year terms; each received over 88% of votes cast.","Ratified Ernst & Young as independent auditor for FY2025 with 230M votes for, 457K against, 1.2M abstentions.","Advisory say-on-pay approved with 169.5M votes for, 37.4M against, 2.6M abstentions; broker non-votes 22.2M.","Quorum established with 231.7M shares present out of 254.6M outstanding as of March 24, 2025 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}